Crossmark

Oligometastatic head and neck cancer: Which patients benefit from radical local treatment of all tumour sites?

Published Online: 2021-03-31

Published Print: 2021-12

Authors

Weissmann, Thomas

Höfler, Daniel

Hecht, Markus

Semrau, Sabine

Haderlein, Marlen

Filimonova, Irina

Frey, Benjamin

Bert, Christoph

Lettmaier, Sebastian

Mantsopoulos, Konstantinos

Iro, Heinrich

Fietkau, Rainer

Putz, Florian https://orcid.org/0000-0003-3966-2872
Funding

Funding for this research was provided by:

Interdisciplinary Center for Clinical Research (IZKF) Erlangen

Friedrich-Alexander-Universität Erlangen-Nürnberg
License Information

Text and Data Mining valid from 2021-03-31

Version of Record valid from 2021-03-31
More Information

Article History

Received: 27 December 2020

Accepted: 17 March 2021

First Online: 31 March 2021

Declarations

:

: Ethical review and written informed consent was not required for participation in this retrospective analysis in accordance with the local legislation (BayKrG Art. 27 (4)) and institutional requirements. Written informed consent for treatment was provided by all patients.

: Not applicable.

: The authors report no conflicts of interest.

Document is current